- Home
- VRDN vs JANX Comparison
VRDN vs JANX Comparison
Compare VRDN & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- JANX
- Stock Information
- Founded
- VRDN 2006
- JANX 2017
- Country
- VRDN United States
- JANX United States
- Employees
- VRDN N/A
- JANX N/A
- Industry
- VRDN Medical Specialities
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- VRDN Health Care
- JANX Health Care
- Exchange
- VRDN Nasdaq
- JANX Nasdaq
- Market Cap
- VRDN 1.3B
- JANX 1.4B
- IPO Year
- VRDN N/A
- JANX 2021
- Fundamental
- Price
- VRDN $15.67
- JANX $24.88
- Analyst Decision
- VRDN Strong Buy
- JANX Strong Buy
- Analyst Count
- VRDN 11
- JANX 7
- Target Price
- VRDN $38.50
- JANX $94.29
- AVG Volume (30 Days)
- VRDN 728.3K
- JANX 646.4K
- Earning Date
- VRDN 08-07-2025
- JANX 08-06-2025
- Dividend Yield
- VRDN N/A
- JANX N/A
- EPS Growth
- VRDN N/A
- JANX N/A
- EPS
- VRDN N/A
- JANX N/A
- Revenue
- VRDN $302,000.00
- JANX $9,336,000.00
- Revenue This Year
- VRDN N/A
- JANX N/A
- Revenue Next Year
- VRDN $17,102.33
- JANX $1,470.82
- P/E Ratio
- VRDN N/A
- JANX N/A
- Revenue Growth
- VRDN 4.86
- JANX 28.12
- 52 Week Low
- VRDN $9.90
- JANX $22.48
- 52 Week High
- VRDN $27.20
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- VRDN 61.91
- JANX 50.69
- Support Level
- VRDN $13.84
- JANX $22.74
- Resistance Level
- VRDN $14.85
- JANX $24.73
- Average True Range (ATR)
- VRDN 0.82
- JANX 1.22
- MACD
- VRDN -0.03
- JANX 0.16
- Stochastic Oscillator
- VRDN 82.81
- JANX 60.13
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.